The Chicago Entrepreneur

FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment

Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

Editorial Team

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Data Update 2 for 2025: The Party Continued (for US Equities)
Next post Bank of America CEO says financial industry will jump into crypto payments if regulators allow it